Page 2 - Mark Erlander News Today

/PRNewswire/ -- Gamma Delta T Cell Therapy represents one of the most promising T Cell therapies in clinical development. The introduction of T cell-based...

FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Jan. 19, 2023 /PRNewswire/ -- Gamma Delta T Cell Therapy represents one of the most promising T Cell therapies in clinical development.

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...

/PRNewswire/ -- The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide markets. The COVID-19...

FinancialNewsMedia.com News Commentary Palm Beach, Fla., Oct. 12, 2022 /PRNewswire/ -- The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth

Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertibs contribution to SoC and position for a possible...

Initial preclinical data in ovarian cancer presented at AACR showed treatment with onvansertib plus olaparib leading to a statistically significant survival...

Bolstered by the success of KRAS G12C inhibitors in lung cancer, smaller firms are developing drugs for a range of other KRAS-mutated cancers and trying to anticipate resistance. 

Reported new Phase 1b/2 data from lead KRAS-mutated metastatic colorectal cancer (mCRC) clinical program showing objective response rate and median...